Monitoring response to treatment in patients utilizing PET

被引：137

作者：

Avril, NE

Weber, WA

机构：

[1] Univ Pittsburgh, Med Ctr, Div Nucl Med, Dept Radiol, Pittsburgh, PA 15213 USA

[2] Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA

来源：

RADIOLOGIC CLINICS OF NORTH AMERICA | 2005年 / 43卷 / 01期

关键词：

D O I：

10.1016/j.rcl.2004.09.006

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Positron emission tomography (PET) exploits a number of biologic tumor characteristics including glucose metabolism, cell proliferation, amino acid transport and synthesis, and hypoxia. PET using [F-18] fluorodeoxyglucose (FDG) provides more sensitive and more specific information about the extent of disease than morphologic-anatomic imaging alone and it is a powerful modality for determination of response to treatment. The metabolic information from FDG-PET is also superior compared with anatomic imaging in detecting residual viable tumor tissue after completion of treatment. Recent developments in instrumentation and the use of new tracers targeting cell proliferation and amino acid transport and synthesis hold promise to augment the application of PET in cancer patients in the future.

引用

页码：189 / +

页数：17

共 81 条

[1] Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer:: correlation with endorectal ultrasound and histopathology [J].

Amthauer, H ;

Denecke, T ;

Rau, B ;

Hildebrandt, B ;

Hünerbein, M ;

Ruf, J ;

Schneider, U ;

Gutberlet, M ;

Schlag, PM ;

Felix, R ;

Wust, P .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (06) :811-819

[2]

Arslan Nuri, 2002, Mol Imaging Biol, V4, P301, DOI 10.1016/S1536-1632(02)00011-2

[3]

Avril N, 2004, J NUCL MED, V45, P930

[4]

Bancewicz J, 2002, LANCET, V359, P1727

[5] Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET [J].

Bokemeyer, C ;

Kollmannsberger, C ;

Oechsle, K ;

Dohmen, BM ;

Pfannenberg, A ;

Claussen, CD ;

Bares, R ;

Kanz, L .

BRITISH JOURNAL OF CANCER, 2002, 86 (04) :506-511

[6]

Brücher BLDM, 2001, ANN SURG, V233, P300

[7] FDG pet studies during treatment:: Prediction of therapy outcome in head and neck squamous cell carcinoma [J].

Brun, E ;

Kjellén, E ;

Tennvall, J ;

Ohlsson, T ;

Sandell, A ;

Perfekt, R ;

Wennerberg, J ;

Strand, SE .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (02) :127-135

[8]

Buck AK, 2002, CANCER RES, V62, P3331

[9] Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J].

Buyse, M ;

Thirion, P ;

Carlson, RW ;

Burzykowski, T ;

Molenberghs, G ;

Piedbois, P .

LANCET, 2000, 356 (9227) :373-378

[10] 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation [J].

Calvo, FA ;

Domper, M ;

Matute, R ;

Martínez-Lázaro, R ;

Arranz, JA ;

Desco, M ;

Alvarez, E ;

Carreras, JL .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02) :528-535

← 1 2 3 4 5 6 7 8 9 →